BiopharmaWatch’s Post

Fierce Pharma released their Fierce 15 labeling the top 15 Biotech companies who are leading the way of the future and breaking down barriers. Over the next few weeks i will be posting daily company spotlights deepdiving into the companies on this list telling you all funding activity and the real reasons they are on this list. Companies such as Abdera Therapeutics, Ascidian Therapeutics and BigHat Biosciences plus many more can be seen all on my page. 👀 Keep your eyes peeled... #Companyspotlight #CRO #Contractresearch #ClinicalResearch #Fierce15 #Biotech #Pharmaceuticals

Acute Respiratory Distress Syndrome (#ARDS) Market Analysis by DelveInsight Business Research LLP Explore the latest insights into the Acute Respiratory Distress Syndrome (ARDS) Market with DelveInsight's comprehensive report! Uncover key trends, market dynamics, and #ARDSTreatment developments shaping the future of ARDS. The leading #ARDSCompanies working in the market are BIOMARCK PHARMACEUTICALS, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB), APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) 3P Biopharmaceuticals, MediciNova, Inc., Edesa Biotech, Inc., Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Inc., Veru Inc., Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO PHARMA, and others. Stay informed and ahead in this evolving #healthcaresegment. Get More Insights @ https://lnkd.in/dySkj8bN #ARDSMarket #HealthcareInsights #DelveInsight #RespiratoryHealth #MarketResearch #PharmaUpdates #HealthcareInnovation

Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinocerebellar Ataxias pipeline constitutes 10+ key companies continuously working towards developing 12+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

OPCU - Partner Week: Biotech's developing large molecule drugs should attend, finding the right outsourcing partner is critical to drug development strategy! At OPCU events, get your questions answered and find out what you need to know within your selection process of working with CDMO partners, timing , capabilities and cultural fit can all be assessed at the Outsourced Pharma Capacity Update. Just Ask for a follow up meeting after the presentation!

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 17.8% 𝗳𝗿𝗼𝗺 2023 𝘁𝗼 2028 Download Free Sample Report-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Companies Working in the Market SteinCares Windrose Consulting Group  Connexion Healthcare CuriRx, Inc Aquavit Pharmaceuticals, Inc   Adello Biologics, LLC Juno Pharmaceuticals Canada Globyz Biopharma Services STC Biologics Inc Nature's Toolbox, Inc. (NTx)   Organon Canada CIRION BioPharma Research BioFactura, Inc. Teva Canada Tanvex CDMO Plexus Ventures LLC BioTools, Inc. PlantForm Corporation Custom Biologics Biosciences Corp LLC The Alinea Group BioTechLogic, Inc. Dahlia Consulting BioPharmaSpec MRM Proteomics Inc. Celltrion Healthcare Canada Limited Toc Toc Communications Hetero México Immuni T

"The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Companies Working in the Market" ... - Appreciate the Dahlia Consulting Shout Out! #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #PMOStrategies #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #StartupSuccess #CompliancewithPharma #OptimizingBusinessPerformance #Consulting #EfficientProjectDelivery #SuccessThroughPMO #PMO #ProjectManagementExcellence #PMOImplementation #Biosimilars #BioPharmaIndustry #BioPharmaceuticalConsulting #Pharmefex #Collaboration #PharmefexConsulting #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharma #Pharmaceuticals #RegenerativeMedicine #HealthcareIndustryNews #BiosimilarsMarket #GlobalBiosimilarsMarket #CAGR #MarketsAndMarkets #DahliaConsultingAccolades

#ADCs and #Bispecifics have achieved notable successes, but they come with limitations. The fusion of these two modalities into #BsADCs has proven to bypass challenges like drug resistance and off-target #toxicities. It's no wonder this field has surged by 114% since 2023, with 146 drugs in the space currently. Some of the developers stepping into this space in 2024: 🔍 XYone Therapeutics Inc.: MUC-1 x MUC-1 🔍 VelaVigo (VBC101-F11): EGFR x c-MET 🔍 VelaVigo (VBC103): TROP-2 x Nectin-4 🔍 Thelper (THEL-003): CD3 x GPCRs 🔍 SPARX BIOPHARMACEUTICAL CORP (PSX-603): PD-L1 x VEGF 🔍 RemeGen Biosciences: TROP-2 x TROP-2  🔍 neoX Biotech (NXV01c): c-MET x EGFR Most BsADCs are in #preclinical development, with no drugs #approved yet—signalling immense #market potential. Drug developers now have a unique opportunity to lead the charge in bringing the first BsADCs to market. Let's hope these #molecules will achieve the success in later stages that they promise. Below is an analysis of the top #targets involved in BsADCs with more than four molecules under investigation & their #payload #mechanism: #biopharma #oncology #innovation #drugconjugates

Combining the strengths of #ADCs and #Bispecifics into a single modality offers an interesting approach to overcoming challenges in oncology treatment. It will be great to see which bispecific ADCs progress successfully through clinical development. #Oncology #DrugDevelopment 

Wondering what makes KBI Biopharma different from other CDMOs? Hear it from Séverine Fagète. It's still time to engage in a conversation with her at booth 710 about your needs and find out the best custom-made solution for you. #FestivalofBiologics

Vol. 21, 2024 雅法全球生物医药交易周报 YAFO Weekly Global Wrap-up Report From July 5 to 12, a total of 13 licensing and cooperation agreements were finalized globally, with 4 deals emerging from the China Biotech Industry. Keymed Biosciences and Belenos Biosciences signed an out-licensing agreement for two pre-clinical stage assets valued at $185 million. Foreseen Biotechnology and Ipsen also secured an out-licensing deal for a pre-clinical stage asset, totaling $1,030 million. AFT Pharmaceuticals and Hainan Haiyao signed an in-licensing agreement for the approved asset Crystaderm. Additionally, a domestic deal was made between InnoventBiologics and IASO Bio for the approved drug FUCASO® (EquecabtageneAutoleucel). On the global front, 9 deals were concluded this week. The most notable agreement was between Ensol Biosciences and Spine BioPharma for the licensing of Vicatertide, amounting to $155 million.  #GlobalPharma #Biotech #PharmaDeals #LicensingAgreements https://lnkd.in/gSTXH_GE